Apogee's Year-Long Study Shows Deepening Skin Improvements With Just Two To Four Doses A Year

Apogee Therapeutics reported encouraging one-year Phase 2 APEX results for Zumilokibart, a next-generation antibody for moderate-to-severe atopic dermatitis, indicating maintenance of patient improvements at one year. The readout supports continued development of the asset and could modestly re-rate the stock as investors reassess the drug’s clinical potential and pathway to pivotal trials or partnerships.

Analysis

Apogee Therapeutics reported encouraging one-year Phase 2 APEX results for Zumilokibart, a next-generation antibody for moderate-to-severe atopic dermatitis, indicating maintenance of patient improvements at one year. The readout supports continued development of the asset and could modestly re-rate the stock as investors reassess the drug’s clinical potential and pathway to pivotal trials or partnerships.